Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathy Medvik"'
Autor:
Michael M. Lederman, M. R. Sandhya Rani, Benigno Rodriguez, Kathy Medvik, Sara J. Conry, Johan K. Sandberg, Alan L. Landay, Ronald E. Blanton, Yngve Falck-Ytter, Donald D. Anthony
Publikováno v:
The Journal of Infectious Diseases. 206:969-973
Disease progression of human immunodeficiency virus type 1 (HIV-1) is associated with immune activation. Activation indices are higher during coinfection of hepatitis C virus (HCV) and HIV. The effect of immune activation on interferon α (IFN-α) th
Autor:
Julie K. Jadlowsky, Ronald S. Veazey, Heather A. Pilch-Cooper, Thomas J. Hope, Mark R. Chance, Brian Clagett, Ronald G. Collman, Kathy Medvik, Valentina Mercanti, Nadeene E. Riddick, Michael M. Lederman, James A. Hoxie, Jean-Michel Escola, Scott F. Sieg, Ann Koons, Oliver Hartley, Donald E. Mosier, Robin E. Offord, Janna Kiselar
Publikováno v:
Blood, Vol. 118, No 4 (2011) pp. 1015-9
Blood
Blood
CC Chemokine Receptor 5 (CCR5) is an important mediator of chemotaxis and the primary coreceptor for HIV-1. A recent report by other researchers suggested that primary T cells harbor pools of intracellular CCR5. With the use of a series of complement
Publikováno v:
Clinical Immunology. 102:154-161
To evaluate the effects of the timing of highly active antiretroviral therapy (HAART) on immune reconstitution, we compared lymphocyte subpopulations and lymphocyte proliferation (LP) in response to Candida albicans, cytomegalovirus, HIV p24, Mycobac
Autor:
Rajesh T Gandhi, Lu Zheng, Ronald J Bosch, Ellen S Chan, David M Margolis, Sarah Read, Beatrice Kallungal, Sarah Palmer, Kathy Medvik, Michael M Lederman, Nadia Alatrakchi, Jeffrey M Jacobson, Ann Wiegand, Mary Kearney, John M Coffin, John W Mellors, Joseph J Eron, AIDS Clinical Trials Group A5244 team
Publikováno v:
PLoS Medicine, Vol 7, Iss 8 (2010)
PLoS Medicine
PLoS Medicine
In a double-blind trial, Rajesh Gandhi and colleagues detect no significant reduction in viral load after people with low-level HIV viremia added an integrase inhibitor to their treatment regimen.
Background Most HIV-1-infected patients on effec
Background Most HIV-1-infected patients on effec
Autor:
Michael Marotta, Bikram Chakraborty, Kathy Medvik, Scott F. Sieg, Aaron Weinberg, Michael M. Lederman, Miguel E. Quiñones-Mateu, Muneer Mirza, Héctor R. Rangel, Bin Jiang, Patti Kiser, Zhimin Feng, Jan Weber
Publikováno v:
AIDS (London, England). 17(16)
OBJECTIVE Mechanisms underlying mucosal transmission of HIV-1 are incompletely understood. We describe the anti-HIV-1 activity of human beta-defensins (hBD), small cationic molecules that provide protection at mucosal surfaces. METHODS AND RESULTS HI